By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: 206-582-1600 Fax: n/a


Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.

Key Statistics

Ownership: Private

Web Site: Juno Therapeutics
Employees: n/a
Symbol: JUNO


Company News
Juno Therapeutics (JUNO) CEO and CFO Earn Hefty Bonuses; Poaches Ex-Amgen (AMGN), Dendreon (DNDN) Scientists 2/25/2015 6:12:58 AM
Juno Therapeutics (JUNO) To Present At March 2015 Investor Conferences 2/24/2015 10:23:20 AM
Booming Juno Therapeutics (JUNO) to Boost Headcount With New Manufacturing Site in Washington 2/9/2015 7:19:55 AM
Juno Therapeutics (JUNO) To Present At 2015 Leerink Global Healthcare Conference 2/5/2015 1:25:23 PM
Juno Therapeutics (JUNO) CEO Eyes New Commercial Immunotherapy Treatment Facility for 2015 1/14/2015 4:51:10 PM
J.P. Morgan: Juno Therapeutics (JUNO) Touts 10 New Drugs for Six Diseases, Loves New CAR-T Platform 1/14/2015 11:05:02 AM
Reasons Juno Therapeutics (JUNO) Is The Biotech Of The Year 1/5/2015 6:55:59 AM
Juno Therapeutics (JUNO) Announces Closing Of Initial Public Offering, Including Full Exercise Of Underwriters’ Option To Purchase Additional Shares 12/24/2014 9:08:46 AM
Juno Therapeutics (JUNO) CEO Pockets $100 Million in IPO; Largest Investor Makes $1 Billion 12/23/2014 6:18:33 AM
Juno Therapeutics Announces Pricing Of Initial Public Offering 12/19/2014 12:46:15 PM